Exchange: NASDAQ·Updated 04:25 AM EDT
SUPN logo

SUPN Supernus Pharmaceuticals Inc

$44.30
$0.33
(0.75%)
Pre-Market
Prev Close $43.97
EarningsNov 3
Mkt Cap$2.56B
Vol206.00

About SUPN

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
41

Bearish Sentiment

How do you feel about SUPN?

Advertisement|Remove ads.